سعر روفاميسين 1.5 مليون وحدة 16 قرص 2022

Rovamycin 1.5 M.I.U. 16 tablets (spiramycin 1.5 million IU) tablets by Sanofi, a macrolide antibiotic; pack of 16 tablets.

• Documented group A beta-haemolytic streptococcal tonsillitis/pharyngitis, as an alternative to beta-lactams, especially when they cannot be usedBase de données publique des médicaments (ANSM)
• Acute sinusitis (when beta-lactam treatment is impossible)Base de données publique des médicaments (ANSM)
• Superinfection of acute bronchitis and exacerbations of chronic bronchitisBase de données publique des médicaments (ANSM)

• Very common: occasional transient paraesthesia. Common: abdominal pain, nausea, vomiting, gastralgia, diarrhoea, pseudomembranous colitis, rash, transient dysgeusia. Frequency not known: QT prolongation, ventricular arrhythmia/torsades de pointes, vasculitis (including Henoch-Schönlein purpura), anaphylactic shock, urticaria, pruritus, angioedema, SJS/TEN/AGEP, cholestatic or mixed hepatitis, leucopenia, neutropenia, haemolytic anaemia. Very rare: liver test abnormalities.International label, equivalent formulation · Base de données publique des médicaments (ANSM)

• Hypersensitivity to spiramycin or to any of the excipients.International label, equivalent formulation · Base de données publique des médicaments (ANSM)
• Children under 6 years of age, because the tablet form carries a risk of choking (false passage).International label, equivalent formulation · Base de données publique des médicaments (ANSM)

• Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis) have been reported; their signs require stopping treatment and contraindicate any re-use of spiramycin alone or combined.International label, equivalent formulation · Base de données publique des médicaments (ANSM)
• Very rare haemolytic anaemia has been reported in patients with G6PD deficiency; use in this population is not recommended.International label, equivalent formulation · Base de données publique des médicaments (ANSM)
• QT prolongation has been reported with macrolides including spiramycin; use with caution in patients with risk factors (uncorrected hypokalaemia/hypomagnesaemia, congenital long QT, heart disease, QT-prolonging drugs; elderly, neonates and women may be more sensitive).International label, equivalent formulation · Base de données publique des médicaments (ANSM)

• Drugs causing torsades de pointes (class Ia/III antiarrhythmics, sultopride, other torsadogenic drugs)Increased risk of ventricular arrhythmias, notably torsades de pointes (precaution for use).Base de données publique des médicaments (ANSM)
• Levodopa (with carbidopa)Inhibition of carbidopa absorption with lower levodopa plasma levels; clinical monitoring and possible levodopa dose adjustment.Base de données publique des médicaments (ANSM)
• Hydroxychloroquine or chloroquineUse with caution because of possible serious cardiovascular adverse effects (QT prolongation, arrhythmias, torsades de pointes) and increased cardiovascular mortality.Base de données publique des médicaments (ANSM)

• Spiramycin may be considered during pregnancy if needed; wide use in pregnancy has not shown malformative or foetotoxic effects to date.International label, equivalent formulation · Base de données publique des médicaments (ANSM)
• Passage into breast milk is significant and digestive disorders have been described in newborns; breastfeeding is not advised during treatment.International label, equivalent formulation · Base de données publique des médicaments (ANSM)

English text not available for this section.